BioTelemetry (NASDAQ:BEAT) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, November 9th, BidAskClub reports.
Several other equities research analysts have also recently commented on BEAT. Sidoti lowered their target price on BioTelemetry from $95.00 to $87.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Raymond James cut shares of BioTelemetry from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. ValuEngine raised shares of BioTelemetry from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Zacks Investment Research cut shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Friday, August 2nd. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $80.00 price target (down previously from $90.00) on shares of BioTelemetry in a research report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $71.83.
Shares of NASDAQ:BEAT traded up $1.69 during trading on Friday, reaching $45.73. 16,541 shares of the stock were exchanged, compared to its average volume of 277,188. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.35 and a current ratio of 2.46. BioTelemetry has a 12-month low of $37.07 and a 12-month high of $80.92. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of 23.54, a price-to-earnings-growth ratio of 2.24 and a beta of 1.31. The firm’s 50-day moving average price is $41.53 and its 200 day moving average price is $44.43.
BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.52 EPS for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.02. BioTelemetry had a return on equity of 21.77% and a net margin of 8.98%. The firm had revenue of $111.30 million during the quarter, compared to the consensus estimate of $111.19 million. During the same period in the prior year, the business earned $0.53 EPS. The firm’s revenue was up 11.3% on a year-over-year basis. As a group, equities research analysts forecast that BioTelemetry will post 1.96 EPS for the current year.
In other BioTelemetry news, SVP Peter Ferola sold 44,276 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $39.03, for a total value of $1,728,092.28. Following the sale, the senior vice president now owns 19,622 shares in the company, valued at $765,846.66. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.50% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of the stock. New England Research & Management Inc. lifted its stake in BioTelemetry by 2.4% during the third quarter. New England Research & Management Inc. now owns 11,675 shares of the medical research company’s stock worth $476,000 after purchasing an additional 275 shares during the last quarter. HMS Capital Management LLC boosted its position in shares of BioTelemetry by 3.8% during the 2nd quarter. HMS Capital Management LLC now owns 8,205 shares of the medical research company’s stock worth $395,000 after purchasing an additional 300 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in BioTelemetry by 3.1% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 13,298 shares of the medical research company’s stock valued at $640,000 after acquiring an additional 400 shares in the last quarter. Flinton Capital Management LLC lifted its position in BioTelemetry by 13.1% in the 2nd quarter. Flinton Capital Management LLC now owns 3,584 shares of the medical research company’s stock valued at $173,000 after acquiring an additional 416 shares in the last quarter. Finally, Meadow Creek Investment Management LLC lifted its position in BioTelemetry by 13.1% in the 2nd quarter. Meadow Creek Investment Management LLC now owns 4,928 shares of the medical research company’s stock valued at $237,000 after acquiring an additional 572 shares in the last quarter. Institutional investors own 90.43% of the company’s stock.
BioTelemetry Company Profile
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Recommended Story: Fundamental Analysis and Choosing Stocks